New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:10 EDTRCPTReceptos risk/reward attractive following data, says Leerink
Leerink believes the Phase II data for RPC-1063 suggests the drug is meaningfully differentiated from other therapies in development at least for patients with relapsing forms of multiple sclerosis. The firm reiterates an Outperform rating on shares of Receptos with a $75 price target and views the risk/reward as attractive.
News For RCPT From The Last 14 Days
Check below for free stories on RCPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 22, 2014
11:01 EDTRCPTBiotechnology Value Fund reports 5.3% passive stake in Receptos
Subscribe for More Information
August 18, 2014
16:29 EDTRCPTARCH Venture Fund reports 6.6% stake in Receptos
Subscribe for More Information
August 13, 2014
08:37 EDTRCPTReceptos assumed with an Outperform at Leerink
Subscribe for More Information
August 12, 2014
07:39 EDTRCPTReceptos reports Q2 EPS ($1.04), consensus (85c)
Subscribe for More Information
August 11, 2014
15:32 EDTRCPTNotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use